

## **Alligator Bioscience AB, Annual General Meeting**

**Lund, Sweden – At Alligator Bioscience's Annual General Meeting on 15 April, CEO Gun-Britt Fransson informed the shareholders about Alligators' progress. Her presentation focused on the progress of the Company as a whole and of the individual projects. Gun-Britt Fransson who steps down as CEO on April 16<sup>th</sup> was recognized for her contributions to Alligators progress over the last 5 years and Paula Zeilon was welcomed as Interim CEO.**

Gun-Britt Fransson described 2009 as a successful year with good progress in the projects. Alligator's drug candidate against acute inflammation in Myocardial Infarction (ADC-1004) has been shown to substantially reduce the size of myocardial infarction in an experimental model in pigs. In addition, supportive results were seen in preliminary studies of lung transplantation in pigs and stroke in rats.

A new research and development platform for immunotherapy in cancer (IMCAN), with a focus on local administration of immunoregulating protein drugs, was started in collaboration with prominent academic researchers in immunology, immunotechnology and nanotechnology.

Two collaborations with commercial partners were started in 2009:

a research and development collaboration with BioInvent under the IMCAN platform, as well as a product development collaboration with an undisclosed U.S. -based company within the area of autoimmune diseases. An important FIND patent was approved in Japan, which means that the technology now covers all the commercially important markets. Alligator now have 19 granted patents and 14 patent applications pending for its method. In addition the company has 3 granted patents and 12 patent applications for its products.

The AGM voted in favor of adopting the income statements and balance sheets for the company. The AGM also decided that the loss of 2009, amounting to SEK 31 377 399 should be accounted for as suggested by the board.

The AGM discharged the Board members and the CEO from liability, voted for the suggestion of 4 board members and reelected the Board members: Karl Olof Borg, Carl Borrebaeck, Mats Grahn and Kenth Petersson.

The Board's fees were set unchanged from previous year at SEK 425 000, of which SEK 170 000 should be the fee for the Chairman of the Board and SEK 85 000 should be the fee for each other member of the board.

In accordance with the board's proposal, the right to decide on emission of new shares with a maximum increase of 10% of the share capital, was adopted by the AGM.

– END –

For further information, please contact:

Alligator Bioscience AB  
Paula Zeilon  
CEO,acting

Phone: +46 46 286 42 95

Mobile: +46 703 265 845

Email: paz@alligatorbioscience.com